Targeting Chromosomal Instability and Tumour Heterogeneity in HER2-Positive Breast Cancer

被引:44
作者
Burrell, Rebecca A. [1 ]
Juul, Nicolai [2 ]
Johnston, Stephen R. [3 ]
Reis-Filho, Jorge S. [4 ]
Szallasi, Zoltan [2 ,5 ]
Swanton, Charles [1 ,3 ]
机构
[1] London Res Inst, Translat Canc Therapeut Lab, London WC2A 3PX, England
[2] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark
[3] Royal Marsden Hosp, Breast Unit, Dept Med, Sutton SM2 5PT, Surrey, England
[4] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[5] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol CHIP HST, Childrens Hosp Informat Program, Boston, MA 02115 USA
关键词
CHROMOSOMAL INSTABILITY; HER2; BREAST CANCER; DRUG RESISTANCE; TUMOUR HETEROGENEITY; MICROTUBULE; CEP17; SPINDLE ASSEMBLY CHECKPOINT; TAXOL-INDUCED APOPTOSIS; IN-SITU HYBRIDIZATION; PHASE-II TRIAL; MITOTIC CHECKPOINT; 1ST-LINE TREATMENT; INTRATUMORAL HETEROGENEITY; RETROSPECTIVE ANALYSIS; KARYOTYPIC COMPLEXITY; ADJUVANT CHEMOTHERAPY;
D O I
10.1002/jcb.22781
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chromosomal instability (CIN) is a common cause of tumour heterogeneity and poor prognosis in solid tumours and describes cell-cell variation in chromosome structure or number across a tumour population. In this article we consider evidence suggesting that CIN may be targeted and may influence response to distinct chemotherapy regimens, using HER2-positive breast cancer as an example. Pre-clinical models have indicated a role for HER2 signalling in initiating CIN and defective cell-cycle control, and evidence suggests that HER2-targeting may attenuate this process. Anthracyclines and platinum agents may target tumours with distinct patterns of karyotypic complexity, whereas taxanes may have preferential activity in tumours with relative chromosomal stability. A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer. J. Cell. Biochem. 111: 782-790, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:782 / 790
页数:9
相关论文
共 86 条
[51]  
Ott K, 2003, CLIN CANCER RES, V9, P2307
[52]   Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line [J].
Pack, SD ;
Alper, ÖM ;
Stromberg, K ;
Augustus, M ;
Özdemirli, M ;
Miermont, AM ;
Klus, G ;
Rusin, M ;
Slack, R ;
Hacker, NF ;
Ried, T ;
Szallasi, Z ;
Alper, Ö .
CANCER RESEARCH, 2004, 64 (03) :789-794
[53]   HER-2 and topoisomerase II as predictors of response to chemotherapy [J].
Pritchard, Kathleen I. ;
Messersmith, Hans ;
Elavathil, Leela ;
Trudeau, Maureen ;
O'Malley, Frances ;
Dhesy-Thind, Bindi .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :736-744
[54]   HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J].
Pritchard, KI ;
Shepherd, LE ;
O'Malley, FP ;
Andrulis, IL ;
Tu, DS ;
Bramwell, VH ;
Levine, MN .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (20) :2103-2111
[55]   Markers predicting clinical benefit in breast cancer from microtubule-targeting agents [J].
Pusztai, L. .
ANNALS OF ONCOLOGY, 2007, 18 :15-20
[56]   Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation [J].
Reddy, S. K. ;
Rape, M. ;
Margansky, W. A. ;
Kirschner, M. W. .
NATURE, 2007, 446 (7138) :921-925
[57]  
ROBERTS JR, 1990, CANCER RES, V50, P710
[58]   Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J].
Romond, EH ;
Perez, EA ;
Bryant, J ;
Suman, VJ ;
Geyer, CE ;
Davidson, NE ;
Tan-Chiu, E ;
Martino, S ;
Paik, S ;
Kaufman, PA ;
Swain, SM ;
Pisansky, TM ;
Fehrenbacher, L ;
Kutteh, LA ;
Vogel, VG ;
Visscher, DW ;
Yothers, G ;
Jenkins, RB ;
Brown, AM ;
Dakhil, SR ;
Mamounas, EP ;
Lingle, WL ;
Klein, PM ;
Ingle, JN ;
Wolmark, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1673-1684
[59]   Targeting cancer cells by exploiting karyotypic complexity and chromosomal instability [J].
Roschke, AV ;
Kirsch, IR .
CELL CYCLE, 2005, 4 (05) :679-682
[60]   Karyotypic "state" as a potential determinant for anticancer drug discovery [J].
Roschke, AV ;
Lababidi, S ;
Tonon, G ;
Gehlhaus, KS ;
Bussey, K ;
Weinstein, JN ;
Kirsch, IR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (08) :2964-2969